Start here if you're new
what it is
Vivani is a pre-revenue biotech trying to replace frequent injections with tiny implants that release medicine for months.
how it gets paid
Last year Vivani Medical made $0 in revenue.
what just happened
The quarter said the quiet part out loud: $0 revenue and a loss machine still running.
At a glance
C++ balance sheet — some cracks in the foundation
50/100 earnings predictability — expect surprises
FY2025 net loss $(0.43)/share (basic & diluted, filed)
Street FY2026 revenue models — not company-reported P0
1.3 beta
xvary composite: 33/100 — weak
What they do
Vivani is a pre-revenue biotech trying to replace frequent injections with tiny implants that release medicine for months.
Vivani is trying to turn frequent GLP-1 dosing into long-interval implants using NanoPortal. Drug delivery platform → steady release under the skin → so what: if it works, adherence and tolerability improve versus daily or weekly dosing. The team is small; financing and trial execution matter more than storytelling.
How they make money
$0
annual revenue
The products that matter
chronic weight management implant
NPM-139 (semaglutide implant)
Phase 1 planned mid-2026 (company language)
Lead semaglutide implant program (NPM-139). If Phase 1 starts on schedule, you get a dated catalyst; if it slips, the story compresses to cash and dilution.
core catalyst
visual cortical prosthesis
Orion Visual Prosthesis System
6-year data presented in jan 2026
the science is real enough to produce long-duration study data, but the asset is being spun into Cortigent. that means it matters less as a reason to own VANI from here.
being separated
corporate simplification
Cortigent spin-off
Form S-1/A filed mar 3, 2026
this is not a product, but it is a real piece of the thesis. if the separation closes cleanly, you get a cleaner read on whether Vivani is just the obesity implant story.
story cleanup
Key numbers
$16.2M
cash (Dec 31, 2025)
Cash and equivalents per the Mar 26, 2026 results release — runway into mid-2027 is management’s framing, not a guarantee.
$0
ttm revenue
No sales means there is nothing operating to value today. You are paying for a trial result, not a business line.
$41.5M
gross proceeds (programs)
Cumulative gross proceeds from registered directs, PIPEs, and similar programs in 2025 plus 2026 YTD — per Mar 26, 2026 release (not a single January tranche).
$26.6M
FY2025 net loss
Full-year 2025 net loss in the filed tables — clinical-stage burn with no product revenue yet.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- lease liabilities (filed) ~$18.9M current + non-current operating leases (Dec 31, 2025 tables)
P0: Vivani Q4/FY2025 results (Mar 26, 2026) — https://investors.vivani.com/investors/news-events/press-releases/detail/213/vivani-medical-reports-fourth-quarter-and-full-year-2025 · Form 10-K link on same IR page
Total return vs. market
Return history isn't available for VANI right now.
source: institutional data · return history unavailable
What just happened
filed results
FY2025: still $0 product revenue; net loss ~$26.6M ($(0.43)/share); Q4 net loss ~$6.6M.
Operating expenses are almost entirely R&D and G&A. The Mar 26, 2026 release also reaffirms cash into mid-2027 on current liquidity and commitments — a forward statement, not a balance-sheet fact by itself.
$0
product revenue
$(0.43)
FY2025 EPS
$6.6M
Q4 net loss
the number that mattered
$0 revenue matters most because it tells you every valuation argument still rests on future trials, not current demand.
P0: Vivani Medical Q4 and FY2025 release (Mar 26, 2026) — https://investors.vivani.com/investors/news-events/press-releases/detail/213/vivani-medical-reports-fourth-quarter-and-full-year-2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is clinical start delay or failure for NPM-139 — because there is no revenue base to absorb bad news.
med
NPM-139 slips or disappoints
The lead semaglutide implant is the near-term thesis. If the planned Phase 1 start in mid-2026 slips, or early human data disappoints, the market loses the only obvious reason to pay attention right now.
With $0 revenue, this risk touches 100% of the current story.
med
Cash burn forces more dilution
The page shows $2.63M in cash and $17M in long-term debt. A March 2025 private placement already raised $8.25M. That is your proof that external capital is part of the model.
New financing can preserve the pipeline while reducing your ownership slice.
med
There is no business diversification
Vivani has $0 revenue, 0% market share, and one clearly defined near-term catalyst. This is concentration taken to its logical extreme.
If one program matters this much, one setback matters just as much.
med
Cortigent spin-off adds execution noise
The Mar 3, 2026 S-1/A moves the separation forward, but corporate simplification is still work. If management time drifts toward the spin-off instead of the obesity implant, the market will notice.
Even a cleaner story can hurt if it arrives late or distracts from the only catalyst that matters.
You own a binary clinical story with ~$16.2M cash at Dec 31, 2025, lease-heavy liabilities on the balance sheet, and no product revenue to cushion setbacks.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
NPM-139 Phase 1 start
Management has pointed to the first half of 2026. If that window slips, the stock stops being a milestone countdown and starts being a financing debate.
balance sheet
Cash versus burn each quarter
Track cash, R&D spend, and any new financings. For pre-revenue biotech, liquidity is the whole game between data releases.
corporate
Cortigent spin-off completion
The Mar 3, 2026 S-1/A made the separation tangible. A clean close simplifies the story. A messy one adds noise to a stock that already has enough of it.
ownership
Whether 6.78% institutional ownership starts rising
If professional ownership stays this low after the next milestones, that tells you the market still sees more financing risk than platform value.
Analyst rankings
earnings predictability
50 / 100
middle of the road. in human-speak, the numbers are hard to model because there is barely a business to model yet.
beta
1.3
When the market moves 10%, VANI has historically moved about 13%. Not the wildest stock on earth, but definitely not a bunker.
source: institutional data
Institutional activity
institutional ownership data for VANI is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive